Passionate about Progress
We are a clinical-stage biopharmaceutical company that is developing the investigational therapy Haduvio™ (oral nalbuphine ER) to help patients suffering with chronic cough by targeting the central and peripheral nervous systems.
We are actively conducting chronic cough trials in both idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC) patients. We completed enrollment in our Phase 2a RIVER trial for the treatment of RCC in October 2024 and we expect topline data in the first quarter of 2025. We completed enrollment in our Phase 2b CORAL trial in February 2025 and had a positive sample size re-estimation (SSRE) outcome in December 2024 that resulted in no change to the existing N = 160. Topline results from the CORAL trial for the treatment of chronic cough in patients with IPF are expected in the first half of 2025.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT and we are proud to be part of its vibrant life-science community.
“At Trevi Therapeutics, we are dedicated to the development of Haduvio for patients with chronic cough in Idiopathic Pulmonary Fibrosis and Refractory Chronic Cough. Our team is committed to improving patients’ lives. Each day, we work with the purpose of making a meaningful impact, focused on delivering a therapy for those affected by chronic cough.”
– Jennifer Good, Co-Founder, President & CEO